(Alendronic Acid)
Alendran 70 is a tablet containing the active substance alendronic acid (also known as alendronate), which belongs to a group of non-hormonal medicines called bisphosphonates. Alendran 70 prevents bone loss in postmenopausal women and helps to rebuild bone. It reduces the risk of vertebral and hip fractures.
Alendran 70 is used to treat osteoporosis. Alendran 70 reduces the risk of vertebral and hip fractures.
Osteoporosis is a disease in which bones become thinner and weaker. It is common in postmenopausal women. During menopause, the ovaries stop producing the hormone estrogen, which helps to maintain bone strength. As a result, bone mass decreases and bones weaken. The earlier a woman has menopause, the greater the risk of osteoporosis. Osteoporosis usually starts without symptoms. If left untreated, it can lead to bone fractures. Although fractures can be painful, they may not cause pain in the case of vertebral fractures, which can only be noticed when the patient's height decreases. Fractures can occur during daily activities, as a result of lifting or minor injuries that would not affect a healthy bone. Fractures usually occur in the hip, spine, or wrist and can cause not only pain but also significant discomfort, such as a hunched back ("dowager's hump") and loss of mobility.
During treatment with Alendran 70, your doctor may recommend lifestyle changes that are beneficial for your condition, such as:
quitting smoking:
smoking can contribute to increased bone loss and thus increase the risk of fractures.
exercises:
bones, like muscles, need proper exercise to stay strong and healthy. Before starting exercises, you should consult with your doctor.
proper diet:
your doctor may recommend changing your diet and possibly supplementing it with appropriate preparations (especially calcium and vitamin D supplements).
If any of the above conditions apply to you, do not take the tablets. You should first talk to your doctor and follow their advice.
Before taking Alendran 70, talk to your doctor or pharmacist if:
A dental examination is recommended before starting treatment with Alendran 70. It is essential to maintain good oral hygiene during treatment with Alendran 70. You should have regular dental check-ups during treatment and contact your doctor or dentist if you experience any oral or dental problems, such as loose teeth, pain, or swelling.
Alendran 70 should not be used in children and adolescents under 18 years of age.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take. It is likely that calcium supplements, antacids, and some oral medicines will interfere with the absorption of Alendran 70 when taken at the same time. Therefore, it is essential to follow the instructions in section 3 "HOW TO TAKE ALENDRAN 70". Some medicines used to treat rheumatic diseases or chronic pain, called non-steroidal anti-inflammatory drugs (e.g., acetylsalicylic acid or ibuprofen), may cause gastrointestinal problems. Therefore, caution should be exercised when taking these medicines with Alendran 70.
It is likely that food and drinks (including mineral water) will reduce the effectiveness of alendronate if taken at the same time. Therefore, it is essential to follow the instructions in section 3 "HOW TO TAKE ALENDRAN 70".
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Alendran 70 is only intended for postmenopausal women. You should not take Alendran 70 if you are or think you may be pregnant or are breastfeeding.
Alendran 70 has been reported to cause side effects (such as vision disturbances, dizziness, and severe bone, muscle, or joint pain) that may affect your ability to drive or use machines (see section 4).
This medicine contains 25.2 mg of sodium (the main component of common salt) per tablet, which is 1.26% of the maximum recommended daily intake of sodium for adults.
This medicine should always be taken exactly as advised by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist.
Read the following instructions carefully.
To help the tablet reach your stomach quickly and to reduce the risk of esophageal irritation (the tube that connects your mouth to your stomach), it is very important to follow these instructions:
Do not crush, chew, or allow the tablet to dissolve in your mouth, as this may cause mouth ulcers.
If you accidentally take too many tablets, drink a full glass of milk and contact your doctor immediately. Do not induce vomiting or lie down.
If you miss a dose, take one tablet the next morning after you remember. Do not take two tablets on the same day. Return to your original schedule of taking one tablet once a week on the day you chose.
It is essential to take Alendran 70 for as long as your doctor prescribes it. Since it is not known how long you should take Alendran 70, you should discuss the need to continue taking this medicine with your doctor periodically to ensure it is still right for you. A card with instructions is included with the Alendran 70 package. It contains important information on how to take Alendran 70 properly. If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, Alendran 70 can cause side effects, although not everybody gets them. You should contact your doctor immediatelyif you experience any of the following side effects, which may be serious and require urgent medical attention:
rare (may affect up to 1 in 1000 people):
very common (may affect more than 1 in 10 people):
common (may affect up to 1 in 10 people):
uncommon (may affect up to 1 in 100 people):
rare (may affect up to 1 in 1000 people):
very rare (may affect up to 1 in 10,000 people):
If you experience any side effects, including those not listed in this leaflet, please inform your doctor, pharmacist, or nurse. You can also report side effects directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Poland, tel.: 22 49 21 301, fax: 22 49 21 309, e-mail: ndl@urpl.gov.pl. You can also report side effects to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month. Store in the original package. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is alendronic acid. One film-coated tablet contains 70 mg of alendronic acid (equivalent to 76.188 mg of anhydrous sodium alendronate). The other ingredients are mannitol, croscarmellose sodium type A, magnesium stearate, talc, and anhydrous colloidal silica.
The tablets are white to almost white, round, and marked with the letter "A" on one side and the number "4" on the other side. They are packaged in blisters of 4, 8, and 12 tablets. Not all pack sizes may be marketed.
Ranbaxy (Poland) Sp. z o.o., ul. Kubickiego 11, 02-954 Warsaw, Poland
Alkaloida Chemical Company Zrt., Kabay János u. 29, H-4440 Tiszavasvári, Hungary; Sun Pharmaceutical Industries Europe B.V., Polarisavenue 87, 2132 JH, Hoofddorp, Netherlands
Belgium: Alendromono 70mg tabletten; Germany: Alendronsäure Basics einmal wöchentlich 70 mg Tabletten; Italy: Alendronato SUN 70 mg compresse; Spain: Ácido Alendrónico Semanal SUN 70mg comprimidos EFG
Date of last revision of the leaflet:09.04.2020
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.